The Price of Dementia: Innovative Strategies to Reduce Risk

The Price of Dementia: Innovative Strategies to Reduce Risk

Share

Details

Today, one in three older adults dies with Alzheimer’s or another dementia. It kills more people than do breast cancer and prostate cancer combined, yet only 16 percent of older adults receive regular cognitive assessments during routine checkups. The economic and emotional costs on families, caregivers, and society are staggering. During this session, a panel of experts will discuss the direct and indirect costs of dementia—especially how it disproportionately impacts women and minorities. New research will be revealed regarding the importance of brain health to delay onset, improve overall health, lower costs, and increase clinical trial participation. The discussion will also focus on ways to improve rates of early detection and diagnosis, as well as how to reduce disparities based on gender, race, and income.

Custom Author Text

Moderator

Nora Super
Senior Director, Center for the Future of Aging, Milken Institute

 

Speakers

Norma Coe
Associate Professor, Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania

 

Linda Elam
CEO and Plan President, Amerigroup District of Columbia, Inc.

 

Howard Fillit
Founding Executive Director and Chief Science Officer, Alzheimer's Drug Discovery Foundation

 

George Vradenburg
Chairman and Co-Founder, UsAgainstAlzheimer's

 

Tags